{"id":"W4379336528","doi":"10.1200/jco.2023.41.16_suppl.tps5629","title":"A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; Durvalumab; Oncology; Clinical endpoint; Internal medicine; PARP inhibitor; Pharmacology; Randomized controlled trial; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004011474,0.00299403,0.003839703,0.0006646154,0.0005900712,0.001397037,0.001696857,0.002316008,0.01019001],"category_scores_gemma":[0.003019696,0.001351769,0.002094663,0.0006629805,0.002026308,0.001675606,0.0006939677,0.004020687,0.001591078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001211988,"about_ca_system_score_gemma":0.0025657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001005953,"about_ca_topic_score_gemma":0.002074805,"domain_scores_codex":[0.9988123,0.0006935947,0.00005011974,0.000216286,0.00007233622,0.0001552921],"domain_scores_gemma":[0.9971051,0.0007677249,0.0005966897,0.000309801,0.0001687044,0.001052089],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9697247,0.01880122,0.0005860861,0.0002026104,0.0003987881,0.00003395014,0.0000397201,0.0003484863,0.002904112,0.00009041619,0.0006823368,0.006187567],"study_design_scores_gemma":[0.8932227,0.1045903,0.0007427343,0.000008997805,0.0001843681,0.00002619353,0.00001374242,0.0003400954,0.0003217023,0.0001221984,0.0004153975,0.00001156753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737176,0.001952503,0.001371265,0.001013857,0.0007558333,0.01580242,0.002679468,0.0001835528,0.002523533],"genre_scores_gemma":[0.9632019,0.001668965,0.005330401,0.002097944,0.0008200979,0.01788976,0.003039903,0.00006934209,0.005881705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01019001,"threshold_uncertainty_score":0.03408897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2684857014458186,"score_gpt":0.4735416012764046,"score_spread":0.205055899830586,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}